Clicky

It is important to note that the company’s actual results could differ materially from those in any such forward-looking statements. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release. Peregrine has provided a $2 million research grant to the NCCN’s Oncology Research Program (ORP) to conduct multiple investigator-initiated clinical and correlative studies with bavituximab in a variety of tumor types. Bavituximab-coated magnetic beads specifically removed infectious Pichinde virus, confirming that infectious virions carry external phosphatidylserine (Fig. by contributing institutions or for the use of any information through the EurekAlert system. If you have one type of HSV, then it is not possible to get that same type again from a new partner. herpes simplex virus is a major cause of neonatal infection, which can lead to death or long-term disability.

The company is pursuing multiple clinical programs in cancer and hepatitis C virus infection with its lead product candidate bavituximab and novel brain cancer agent Cotara®. In this context, antibodies represent an intriguing alternative as therapeutics; in their favor are their different resistance mechanisms and a more favorable toxicity profile when compared to other available drug classes, fitting them for use in conjunction with the current chemotherapy by slowing the onset of resistance and possibly enhancing therapeutic efficacy. The company is pursuing multiple clinical programs in cancer and hepatitis C virus infection with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Thorpe recruited Dr. TUSTIN, Calif., Nov. In 2008, Peregrine was awarded a five-year research contract worth up to $44.4 million by the Defense Threat Reduction Agency for the Transformational Medical Technologies Initiative (TMTI). disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.


PS-targeting antibodies such as bavituximab bind to PS and block the immunosuppressive signals created by the target, thereby allowing the immune system to mount a robust immune response against the pathogen. In 2008, Peregrine was awarded a five-year research contract worth up to $44.4 million by the Defense Threat Reduction Agency for the Transformational Medical Technologies Initiative (TMTI). Peregrine Pharmaceuticals, Inc. The side effects of immunotherapy are different than chemotherapy. In 2008, Peregrine was awarded a five-year research contract worth up to $44.4 million by the Defense Threat Reduction Agency for the Transformational Medical Technologies Initiative (TMTI). Bavituximab is currently being studied in clinical trials for treatment against hepatitis C virus (HCV) and in preclinical trials for treatment against HIV, cytomegalovirus (CMV), viral hemorrhagic fever and other serious viral infections. “Though standard treatment for chronic HCV may soon evolve with the introduction of new targeted antiviral drug candidates, immune stimulation with interferon remains a critical component of therapy.

In the case of virus infection, the binding raises a red flag to the body’s immune system, forcing the deployment of defensive white blood cells to attack the infected cells,” Nature magazine quoted Thorpe as saying. fully human) variants of the drug. (www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. with funding from the Bill and Melinda Gates Foundation and the National Institutes of Allergy and Infectious Diseases (NIAID). The company is pursuing multiple clinical programs in cancer and infectious diseases with its lead product candidate bavituximab and novel brain cancer agent Cotara®. He held postdoctoral positions at the University of Michigan and the Vollum Institute of Advanced Biomedical Research (1991, 1989). In Journal of Hepatology Supplement 1 46th Annual Meeting of the European Association for the Study of the Liver (EASL) 2011 Mar 30 – Apr 4; Berlin, Germany.

and U.K. Patient cohorts received ascending dose levels of bavituximab weekly for up to 8 weeks. PS is a unique marker exposed on the surface of virally infected cells that can be targeted to treat a broad spectrum of virus infections. Question: Have you conducted additional Bavituximab studies with any of the viruses mentioned in the Nature Medicine article or with the herpes (oral/genital) and Epstein Bar (EBV) viruses? Barton Haynes and colleagues at Duke University Medical Center. Bavituximab showed potent anti-viral activity in both models. Padmanee Sharma, M.D., Ph.D., and colleagues discovered a cellular pathway whose activation seems be important for having a good response to ipilimumab.

The results are representative of two separate experiments. Provide the facts, and let your child know where you stand. Remember: you can get herpes from someone who has no sores or symptoms and if you have herpes you can spread it even if you have no sores or symptoms. Should Bavituximab be “fast tracked” through the FDA process in light of the millions of people who are sick and dying from viral-based diseases? TUSTIN, CA, and BERLIN, GERMANY–(Marketwire – April 4, 2011) – Peregrine Pharmaceuticals, Inc. Many nonicosohedral viruses that bud out from the plasma membrane are assembled in, and bud out of, membrane microdomains, commonly called ‘rafts’20.